Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells

Journal of Pineal Research

Volumn 41, Issue 4, 2006, Pages 358-362

  Cui, Peilin ^a,b   Luo, Zhaohua ^a   Zhang, Honggang ^a   Su, Yan ^a   Li, Ailing ^a   Li, Hongwei ^a   Zhang, Jing ^a   Yang, Zhaoxu ^b   Xiu, Ruijuan ^a  

^a Chinese Academy of Medical Sciences   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti proliferation; Apoptosis; Human umbilical vein endothelial cell; Melatonin; Tumor

Indexed keywords

DNA FRAGMENT; MELATONIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; UMBILICAL VEIN; UPREGULATION; WESTERN BLOTTING;

CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; MELATONIN; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; UMBILICAL VEINS;

EID: 33749329466     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2006.00375.x     Document Type: Article

References (29)

1. HILL SM, BLASK DE. Effects of the pineal hormone melatonin on the proliferation and the morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48:6121-6126.
2. RAM PT, KIEFER T, SILVERMAN M et al. Estrogen receptor transactivation in the MCF-7 breast cancer cells by melatonin and growth factors. Mol Cell Endocrinol 1998; 141:53-64.
3. VIJAYALAXMI, THOMAS CR, REITER RJ et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20:2575-2601.
4. BLASK DE, SAUER LA, DAUCHY RT. Melatonin as chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian based cancer therapy. Curr Top Med Chem 2002; 2:113-132.
5. SÓNCHEZ-BARCELÓ EJ, COS S, MEDIAVILLA D et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38:217-222.
6. REITER RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37:213-214.
7. FERRARA N, HOUCK KA, JAKEMAN LB et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13:18-32.
8. SALVEN P, MAENPAA H, ORPANA A et al. Serum vascular endothelial growth factor is often evaluated in disseminated cancer. Clin Cancer Res 1997; 3:647-651.
9. LISSONI P, ROVELLI F, MALUGANI F et al. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett 2001; 22:45-47.
10. KAJDANIUK D, MAREK B, KOS-KUDLA B et al. Does the negative correlation found in breast cancer patients between plasma melatonin and insulin-like growth factor-I concentrations imply the existence of an additional mechanism of oncostatic melatonin influence involved in defense? Med Sci Monit 2002; 8:CR457-CR461.
11. SIU SW, LAU KW, TAM PC et al. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52:106-122.
12. GRANT K, LOIZIDON M, TAYLOR I. Endothelin-1: a multifunctional molecular in cancer. Br J Cancer 2003; 88:163-166.
13. JAFFE EA, NACHMAN RL, BECKER CG et al. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-2756.
14. WANG CL, LI HW, FU PF et al. Serum C-reactive protein and circulating endothelial cells in patients with acute myocardial infarction. Clin Hemorheol Microcirc 2005; 32:287-296
15. LISSONI P. The pineal gland as a central regulator of cytokine network. Neuroendocrinol Lett 1999; 20:343-349.
16. WEIDNER N, SEMPLE JP, WELCH WR et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
17. CARMELIET P, JAIN RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
18. SAINZ RM, MAYO JC, RODRIGUEZ C et al. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 2003; 60:1407-1426.
19. PAWLIKOWSKI M, WINCZYK K, KARASEK M. Oncostatic action of melatonin: facts and question marks. Neuro Endocrinol Lett 2002; 23(Suppl. 1):24-29.
20. BURNS TF, BERNHARD EJ, EL-DEIRY WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20:4601-4612.
21. MERCER WE. Cell cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Expr 1992; 2:251-263.
22. JIMENEZ B, VOLPERT OV, CRAWFORD SE et al. Signals leading to apoptosis dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41-48.
23. TRUBIANI O, RECCHIONI R, MORONI F et al. Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res 2005; 39:425-431
24. LEON J, ACUNA-CASTROVIEJO D, EACAMES G et al. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38:1-9.
25. ANTONSSON B. Bax and other pro-apoptotic Bcl-2 family "killerproteins" and their victim the mitochondrion. Cell Tissue Res 2001; 306:347-361.
26. ZORNIG M, HUEBER A, BAUM W et al. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001; 1551:1-37.
27. MIYASHITA T, HARIGAI M, HANADA M et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-3135.
28. ECK-ENRIQUEZ K, KIEFER TL, SPRIGGS LL et al. Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res Treat 2000; 61:229-239.
29. COS S, MEDIAVILLA MD, FERNÓNDEZ R et al. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res 2002; 32:90-96.